Meads Kristy L, Huettner Steve, Amata Dexter, Johnson Hailey, Devine Jaime K, Warnakulasuriya Shenali, Murphy Keith R, Good Cameron H
Attune Neurosciences, Bel Air, MD, United States.
Stevenson University, Owings Mills, MD, United States.
Front Psychiatry. 2024 Nov 29;15:1481795. doi: 10.3389/fpsyt.2024.1481795. eCollection 2024.
Opioid use disorder (OUD) is a serious and persistent problem in the United States with limited non-pharmacological treatment options, especially for the concomitant sleep disorders experienced by most individuals with addiction. While new, non-invasive interventions such as low-intensity focused ultrasound (LIFU) have shown promise in targeting the brain regions impacted throughout addiction and recovery, the devices used are not amenable to outpatient treatment in their current form factor and cannot be used at night during sleep. To bridge this gap and provide a much-needed treatment option for repeated, at-home use, we developed a wearable LIFU device out-of-clinic use.
This study evaluated the feasibility and acceptability of the portable treatment device among individuals recovering from OUD in an unsupervised, at-home setting. 31 subjects were recruited from a Baltimore, Maryland (USA) outpatient treatment facility and, along with a separate group of 14 healthy controls (HC), were asked to wear a prototype EEG-only (non-LIFU) device for 7 consecutive nights to assess their willingness and adherence to nightly use. Participants used a smartphone application, TrialKit (ePRO), to self-report nightly sleep data (e.g. duration, quality, possible disturbances, and device comfort).
Of the 31 OUD participants recruited, 30 (97%) successfully completed the at-home study, and the majority responded that they would participate in future studies using the head wearable device (OUD, 87%; HC, 71%). OUD participants were statistically more likely than HCs to respond that they would consider using the device in the future to help them sleep (OUD, 70%; HC, 29%). Despite some participants facing technological issues (e.g. lack of reliable phone access or cellular data plans), the OUD group demonstrated high study compliance on par with the healthy control group.
Participant's daily ePRO and exit interview results established that at-home use of advanced treatment technology is feasible in a population group challenged with recovering from OUD. Even more so, numerous participants noted strong willingness to participate in future LIFU-enabled intervention studies to address their persistent sleep issues during recovery.
阿片类药物使用障碍(OUD)在美国是一个严重且持续存在的问题,非药物治疗选择有限,尤其是对于大多数成瘾者所伴随的睡眠障碍。虽然诸如低强度聚焦超声(LIFU)等新型非侵入性干预措施已显示出针对成瘾及康复过程中受影响脑区的潜力,但目前使用的设备在其现有外形尺寸下不适合门诊治疗,且不能在夜间睡眠期间使用。为了填补这一空白,并提供一种急需的、可在家中反复使用的治疗选择,我们开发了一种用于门诊外使用的可穿戴LIFU设备。
本研究在无监督的家庭环境中评估了便携式治疗设备在从OUD康复的个体中的可行性和可接受性。从美国马里兰州巴尔的摩的一家门诊治疗机构招募了31名受试者,并要求他们与另一组14名健康对照者(HC)一起,连续7晚佩戴仅用于脑电图(非LIFU)的原型设备,以评估他们每晚使用的意愿和依从性。参与者使用智能手机应用程序TrialKit(电子患者报告结局,ePRO)自我报告每晚的睡眠数据(例如持续时间、质量、可能的干扰和设备舒适度)。
在招募的31名OUD参与者中,30名(97%)成功完成了家庭研究,大多数人表示他们愿意参加未来使用头部可穿戴设备的研究(OUD组为87%;HC组为71%)。与HC相比,OUD参与者在统计学上更有可能表示他们会考虑在未来使用该设备来帮助他们睡眠(OUD组为70%;HC组为29%)。尽管一些参与者面临技术问题(例如缺乏可靠的电话接入或手机数据套餐),但OUD组的研究依从性与健康对照组相当。
参与者的每日ePRO和退出访谈结果表明,在从OUD康复面临挑战的人群中,在家中使用先进治疗技术是可行的。更重要的是,许多参与者表示强烈愿意参加未来启用LIFU的干预研究,以解决他们康复期间持续存在的睡眠问题。